- In April 2024, Bausch Health Companies Inc. announced the launch of an advanced topical treatment designed for the effective management of common and plantar warts, marking a significant step forward in non-invasive wart care. The new product incorporates an enhanced salicylic acid formulation with improved skin tolerance, reflecting Bausch’s commitment to delivering innovative and patient-friendly dermatology solutions. This development aligns with the company’s broader goal of expanding its footprint in the over-the-counter wart treatment segment globally
- In March 2024, Lumenis Ltd., a leading provider of energy-based medical solutions, introduced a next-generation CO₂ laser platform tailored for dermatological procedures, including the precise removal of recalcitrant warts. The system integrates advanced safety protocols and user-centric features aimed at minimizing tissue damage and maximizing procedural efficiency. This advancement underscores Lumenis’s dedication to advancing clinical dermatology through minimally invasive and high-efficacy technologies
- In February 2024, Grace Therapeutics, a biopharmaceutical company focused on topical drug delivery, revealed promising Phase II clinical results for its novel immunotherapeutic gel designed for resistant and recurrent warts. The gel combines a proprietary delivery system with targeted immune activation to enhance wart clearance rates. This milestone highlights the growing interest in immunomodulatory treatments that offer an alternative to destructive therapies, particularly for immunocompromised or pediatric patients
- In January 2024, Meda Pharmaceuticals (a Mylan company) expanded the distribution of its leading wart treatment brand, Verruca-Fix, into key emerging markets across Southeast Asia and Latin America. The strategic expansion aims to address increasing demand for accessible, over-the-counter wart removal solutions in regions with rising skin infection rates. Meda’s move reinforces its objective to improve dermatological care availability through localized distribution strategies and affordable product offerings
- In December 2023, Cutanea Life Sciences, a subsidiary of Maruho Co., Ltd., announced a collaborative research partnership with a U.S. dermatology institute to explore combination therapies for HPV-induced skin conditions, including flat and periungual warts. The research focuses on synergistic effects between cryotherapy and topical immunotherapy agents to enhance treatment efficacy and recurrence prevention. This initiative signals a broader industry push toward integrated wart management protocols backed by clinical research
